Ann Clin Microbiol.  2017 Jun;20(2):27-34. 10.5145/ACM.2017.20.2.27.

Viral Infections in Workers in Hospital and Research Laboratory Settings

• Hong KH

• KMID: 2383228
• DOI: http://doi.org/10.5145/ACM.2017.20.2.27

Abstract

As many emerging human infections are caused by viruses, laboratory-acquired viral infection will become more common. However, additional knowledges is needed, including actual incidence, disinfectant, and prevention. Although the general biosafety principles of viruses do not differ from those of other microorganisms, biosafety guidelines and programs are not immutable and could vary according to virus and laboratory environment. Most laboratory-acquired viral infections reported in the literature were caused by violation of biosafety principles.

Keyword

Laboratory infection; Occupational diseases; Virus diseases

MeSH Terms

Humans
Incidence
Laboratory Infection
Occupational Diseases
Virus Diseases

Reference

1. Sulkin SE, Pike RM. Survey of laboratory-acquired infections. Am J Public Health Nations Health. 1951; 41:769–781.

2. Sulkin SE. Laboratory-acquired infections. Bacteriol Rev. 1961; 25:203–209.

3. Singh K. Laboratory-acquired infections. Clin Infect Dis. 2009; 49:142–147.

4. Pedrosa PB, Cardoso TA. Viral infections in workers in hospital and research laboratory settings: a comparative review of infection modes and respective biosafety aspects. Int J Infect Dis. 2011; 15:e366–e376.

5. Coelho AC, García Díez J. Biological risks and laboratory-acquired infections: a reality that cannot be ignored in health biotechnology. Front Bioeng Biotechnol. 2015; 3:56.

6. Khabbaz R, Bell BP, Schuchat A, Ostroff SM, Moseley R, Levitt A, et al. Emerging and Reemerging Infectious Disease Threats. In : Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Elsevier;2015. p. 158–177.

7. Wurtz N, Papa A, Hukic M, Di Caro A, Leparc-Goffart I, Leroy E, et al. Survey of laboratory-acquired infections around the world in biosafety level 3 and 4 laboratories. Eur J Clin Microbiol Infect Dis. 2016; 35:1247–1258.

8. Korea Centers for Disease Control and Prevention. Pathogen Safety Data Sheets [Risk group 2, 3, 4]. last visited on 27 Feburary 2017. http://cdc.go.kr/CDC/notice/CdcKrTogether0302.jsp?menuIds=HOME001-MNU1154-MNU0005-MNU0088&cid=73019/ [Online].

9. American Biological Safety Association. Risk group database. last visited on 29 January 2017. https://my.absa.org/tiki-index.php?page=Riskgroups/ [Online].

10. Public Health Agency of Canada. Pathogen Safety Data Sheets and Risk Assessment. last visited on 29 January 2017. http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ [Online].

11. Korea Centers for Disease Control and Prevention. Guideline for Laboratory Biosafety. Cheongju: Korea Centers for Disease Control and Prevention;2016.

12. Chosewood LC, Wilson DE. Centers for Disease Control and Prevention (U.S.). National Institutes of Health (U.S.). Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, D.C.: U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institutes of Health;2009.

13. World Health Organizaiton. Laboratory Biosafety Manual. 3rd ed. Geneva, Switzerland: World Health Organization;2004.

14. Lloyd G, Kiley MP. Safety in the Virology Laboratory. In : Mahy BWJ, Meulen VT, editors. Topley and Wilson's Microbiology and Microbial Infections. 10th ed. Hoboken, NJ: John Wiley and Sons;2010.

15. Rusnak J. Occupational Health Manual for Laboratory Exposures to Select (BSL-3 & BSL-4) and Other Biological Agents. USAMRIID (U.S. Army Medical Research Institute of Infectious Diseases). Maryland: Fort Detrick;2011.

16. World Health Organization. Infection Prevention and Control of epidemic- and Pandemic-prone Acute Respiratory Infections in Health Care, WHO Guidelines. Geneva, Switzerland: World Health Organization;2014. p. 14.

17. Gralton J, McLaws ML. Protecting healthcare workers from pandemic influenza: N95 or surgical masks? Crit Care Med. 2010; 38:657–667.

18. De Carli G, Abiteboul D, Puro V. The importance of implementing safe sharps practices in the laboratory setting in Europe. Biochem Med (Zagreb). 2014; 24:45–56.

19. Korea Centers for Disease Control and Prevention. Safety guidance to highly dangerous pathogens. Cheongju: Korea Centers for Disease Control and Prevention;2016.

20. Maillard JY, Sattar SA, Pinto F. Virucidal Activity of Microbicides. In : Fraise AP, Maillard JY, Sattar SA, editors. Principles and Practice of Disinfection, Preservation, and Sterilization. 5th ed. Chichester, West Sussex: John Wiley & Sons;2012. p. 178–207.

21. Maillard JY. Virus susceptibility to biocides: an understanding. Rev Med Microbiol. 2001; 12:63–74.

22. Springthorpe VS, Grenier JL, Lloyd-Evans N, Sattar SA. Chemical disinfection of human rotaviruses: efficacy of commercially-available products in suspension tests. J Hyg (Lond). 1986; 97:139–161.

23. Brown TT Jr. Laboratory evaluation of selected disinfectants as virucidal agents against porcine parvovirus, pseudorabies virus, and transmissible gastroenteritis virus. Am J Vet Res. 1981; 42:1033–1036.

24. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999; 12:147–179.

25. Zeiger E, Gollapudi B, Spencer P. Genetic toxicity and carcinogenicity studies of glutaraldehyde--a review. Mutat Res. 2005; 589:136–151.

26. Nuanualsuwan S, Cliver DO. Pretreatment to avoid positive RT-PCR results with inactivated viruses. J Virol Methods. 2002; 104:217–225.

27. Shin GA, Sobsey MD. Reduction of Norwalk virus, poliovirus 1, and bacteriophage MS2 by ozone disinfection of water. Appl Environ Microbiol. 2003; 69:3975–3978.

28. Resnick L, Veren K, Salahuddin SZ, Tondreau S, Markham PD. Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments. JAMA. 1986; 255:1887–1891.

29. Taylor GR, Butler M. A comparison of the virucidal properties of chlorine, chlorine dioxide, bromine chloride and iodine. J Hyg (Lond). 1982; 89:321–328.

30. Shirai J, Kanno T, Tsuchiya Y, Mitsubayashi S, Seki R. Effects of chlorine, iodine, and quaternary ammonium compound disinfectants on several exotic disease viruses. J Vet Med Sci. 2000; 62:85–92.

31. Ito K, Kajiura T, Abe K. Effect of ethanol on antigenicity of hepatitis B virus envelope proteins. Jpn J Infect Dis. 2002; 55:117–121.

32. Steinmann J, Becker B, Bischoff B, Paulmann D, Friesland M, Pietschmann T, et al. Virucidal activity of 2 alcohol-based formulations proposed as hand rubs by the World Health Organization. Am J Infect Control. 2010; 38:66–68.

33. Kimman TG, Smit E, Klein MR. Evidence-based biosafety: a review of the principles and effectiveness of microbiological containment measures. Clin Microbiol Rev. 2008; 21:403–425.

34. Rusnak JM, Kortepeter MG, Hawley RJ, Anderson AO, Boudreau E, Eitzen E. Risk of occupationally acquired illnesses from biological threat agents in unvaccinated laboratory workers. Biosecur Bioterror. 2004; 2:281–293.

35. MacNeil A, Reynolds MG, Damon IK. Risks associated with vaccinia virus in the laboratory. Virology. 2009; 385:1–4.

36. Petersen BW, Harms TJ, Reynolds MG, Harrison LH. Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses -recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015. MMWR Morb Mortal Wkly Rep. 2016; 65:257–262.

37. Wei Q, Jiang MN, Han J, Wang ZJ. Immune control strategies for vaccinia virus-related laboratory-acquired infections. Biomed Environ Sci. 2014; 27:142–146.

38. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis. 2003; 37:251–271.

39. Wei Q, Lu XC, Wu GZ. Analysis on status and characteristics of laboratory-acquired vaccinia virus infections cases. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2013; 27:73–75.

40. Hsu CH, Farland J, Winters T, Gunn J, Caron D, Evans J, et al. Laboratory-acquired vaccinia virus infection in a recently immunized person--Massachusetts, 2013. MMWR Morb Mortal Wkly Rep. 2015; 64:435–438.

41. McCollum AM, Austin C, Nawrocki J, Howland J, Pryde J, Vaid A, et al. Investigation of the first laboratory-acquired human cowpox virus infection in the United States. J Infect Dis. 2012; 206:63–68.

42. Riyesh T, Karuppusamy S, Bera BC, Barua S, Virmani N, Yadav S, et al. Laboratory-acquired buffalopox virus infection, India. Emerg Infect Dis. 2014; 20:324–326.

43. Centers for Disease Control and Prevention (CDC). Laboratory-acquired West Nile virus infections--United States, 2002. MMWR Morb Mortal Wkly Rep. 2002; 51:1133–1135.

44. Venter M, Steyl J, Human S, Weyer J, Zaayman D, Blumberg L, et al. Transmission of West Nile virus during horse autopsy. Emerg Infect Dis. 2010; 16:573–575.

45. Desmyter J, LeDuc JW, Johnson KM, Brasseur F, Deckers C, van Ypersele de Strihou C. Laboratory rat associated outbreak of haemorrhagic fever with renal syndrome due to Hantaan-like virus in Belgium. Lancet. 1983; 2:1445–1448.

46. Lloyd G, Bowen ET, Jones N, Pendry A. HFRS outbreak associated with laboratory rats in UK. Lancet. 1984; 1:1175–1176.

47. Cho SH, Ju YS, Kang DH, Kim SG, Kim IS, Hong ST. Laboratory-acquired infections with hantavirus at a research unit of medical school in Seoul, 1996. Korean J Prev Med. 1999; 32:269–275.

48. Umenai T, Lee HW, Lee PW, Saito T, Toyoda T, Hongo M, et al. Korean haemorrhagic fever in staff in an animal laboratory. Lancet. 1979; 1:1314–1316.

49. Kawamata J, Yamanouchi T, Dohmae K, Miyamoto H, Takahaski M, Yamanishi K, et al. Control of laboratory acquired hemorrhagic fever with renal syndrome (HFRS) in Japan. Lab Anim Sci. 1987; 37:431–436.

50. Martinez VP, Bellomo C, San Juan J, Pinna D, Forlenza R, Elder M, et al. Person-to-person transmission of Andes virus. Emerg Infect Dis. 2005; 11:1848–1853.

51. Korea Centers for Disease Control & Prevention. Guideline for vector-borne disease control (Rodent) 2016. last visited on 27 Feburary 2017. http://cdc.go.kr/CDC/cms/content/mobile/90/69290_view.html/ [Online].

52. Schmaljohn CS. Vaccines for hantaviruses: progress and issues. Expert Rev Vaccines. 2012; 11:511–513.

53. 2015. 05. 13. last visited on 19 June 2017. http://health.chosun.com/healthcarenews/nh984/2015/05/13/nh98420150513111123164.html/ [Online].

54. Lee C, Jang EJ, Kwon D, Choi H, Park JW, Bae GR. Laboratory-acquired dengue virus infection by needlestick injury: a case report, South Korea, 2014. Ann Occup Environ Med. 2016; 28:16.

55. Britton S, van den Hurk AF, Simmons RJ, Pyke AT, Northill JA, McCarthy J, et al. Laboratory-acquired dengue virus infection--a case report. PLoS Negl Trop Dis. 2011; 5:e1324.

56. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384:1358–1365.

57. Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015; 372:113–123.

58. Lim PL, Kurup A, Gopalakrishna G, Chan KP, Wong CW, Ng LC, et al. Laboratory-acquired severe acute respiratory syndrome. N Engl J Med. 2004; 350:1740–1745.

59. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14:523–534.

60. Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. Br Med J. 1977; 2:541–544.

61. Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation. J Infect Dis. 1999; 179:Suppl 1. S48–S53.

62. Kortepeter MG, Martin JW, Rusnak JM, Cieslak TJ, Warfield KL, Anderson EL, et al. Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit. Emerg Infect Dis. 2008; 14:881–887.

63. Russian Scientist Dies After Ebola Lab Accident. Science. 2004; 304:1225.

64. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 2002; 287:2391–2405.

65. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017; 389:505–518.

66. Barry M, Russi M, Armstrong L, Geller D, Tesh R, Dembry L, et al. Brief report: treatment of a laboratory-acquired Sabiá virus infection. N Engl J Med. 1995; 333:294–296.

67. Ambrosio A, Saavedra M, Mariani M, Gamboa G, Maiza A. Argentine hemorrhagic fever vaccines. Hum Vaccin. 2011; 7:694–700.

68. Kerber R, Reindl S, Romanowski V, Gómez RM, Ogbaini-Emovon E, Günther S, et al. Research efforts to control highly pathogenic arenaviruses: a summary of the progress and gaps. J Clin Virol. 2015; 64:120–127.

69. Filipe AR, Martins CM, Rocha H. Laboratory infection with Zika virus after vaccination against yellow fever. Arch Gesamte Virusforsch. 1973; 43:315–319.

70. Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017; 543:248–251.

71. Li H, Cao B. Pandemic and avian influenza a viruses in humans: epidemiology, virology, clinical characteristics, and treatment strategy. Clin Chest Med. 2017; 38:59–70.

72. World Health Organizaiton. Diseases Outbreak News (DONs) Human infection with avian influenza A(H7N9) virus – China. last visited on 24 Feburary 2017. http://www.who.int/csr/don/20-february-2017-ah7n9-china/en/ [Online].

73. Wong SS, Yuen KY. Avian influenza virus infections in humans. Chest. 2006; 129:156–168.

74. Willemarck N, Van Vaerenbergh B, Descamps E, Brosius B, Thi CDD, Leunda A, et al. Laboratory-Acquired Infections in Belgium (2007-2012) An online survey. 2015.

75. Baz M, Luke CJ, Cheng X, Jin H, Subbarao K. H5N1 vaccines in humans. Virus Res. 2013; 178:78–98.

76. Centers for Disease Control and Prevention. Interim Guidance on Influenza Antiviral Chemoprophylaxis of Persons Exposed to Birds with Avian Influenza A Viruses Associated with Severe Human Disease or with the Potential to Cause Severe Human Disease. last visited on 24 Feburary 2017. https://www.cdc.gov/flu/avianflu/guidance-exposed-persons.htm/ [Online].

77. Berríos EP. Foot and mouth disease in human beings. A human case in Chile. Rev Chilena Infectol. 2007; 24:160–163.

78. David W, Brown G. Foot and mouth disease in human beings. Lancet. 2001; 357:1463.

79. Simmons N, Feldman R. If foot and mouth disease were a disease of human beings. Lancet Infect Dis. 2001; 1:75–76.

80. European Centre for Disease Prevention and Control. Rapid risk assessment: Transmission of Foot and Mouth disease to humans visiting affected areas. last visited on 26 Feburary 2017. http://ecdc.europa.eu/en/publications/Publications/TER-RRA-Transmission-of-foot-and-mouth-to-humans-visiting-affected-areas.pdf/ [Online].